Report Company Directory
- Pharvaris Business update narrows topline prophylactic phase 3 data to 3Q26 by KBC Securities
- Morning Notes : ARGX BB, GBLB BB, MDXH BB, ONTEX BB, UCB BB, AUTL US, PHVS US by KBC Securities
- Pharvaris Outlines 2026 Strategic Priorities by GlobeNewsWire
- Morning Notes : ARGX BB, SOLV BB, PHVS US, ENRGY BB by KBC Securities
- Pharvaris Deucrictibant HAE on-demand phase 3 hits all endpoints by KBC Securities
- RAPIDe-3 Win A Nice Way To Close Out 2025; NDA Submission On Deck In 2026 by Wedbush
- Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks by GlobeNewsWire
- Wedbush Morning Call - Nov 17 2025 6:55AM by Wedbush
- Biotech 3Q25 EPS Wrap-Up: Don't Stop Now, We're In The Home Stretch by Wedbush
- Wedbush Morning Call - Nov 13 2025 7:11AM by Wedbush